Artelo Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARTL research report →
Price Chart
About the company
Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.
- CEO
- Gregory D. Gorgas
- IPO
- 2019
- Employees
- 7
- HQ
- Solana Beach, CA, US
Get TickerSpark's AI analysis on ARTL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.48M
- P/E
- -0.09
- Fwd P/E
- 0.06
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 0.39
- EV/EBITDA
- 0.14
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -519.09%
- ROIC
- -219.36%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-11,404,000
- Net Income
- $-12,879,000-31.1%
- EPS
- $-5.47-438.1%
- OCF Growth
- -2.0%
- FCF Growth
- -2.0%
- 52W High
- $28.98
- 52W Low
- $0.69
- 50D MA
- $1.02
- 200D MA
- $3.64
- Beta
- -0.07
- RSI (14)
- 32
- Avg Volume
- 1.10M
No earnings-call transcripts are available for ARTL yet.
- Free Float
- 62.4%
- Shares Outstanding
- 3.49M
- Float Shares
- 2.17M
of shares held by institutions
9 13F filers
Buy/sell ratio 0.72. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 14.03K | 0 |
| Cwm, LLC | 1 | ▲ 1 |
Held by 4 ETFs
Biggest fund positions in ARTL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 17, 26 | MATSUI CONNIE | other | 136 |
| Jul 17, 26 | Blayney Douglas | other | 136 |
| Jul 17, 26 | Reyes Gregory | other | 136 |
| Jul 17, 26 | EMANUELE ROBERT MARTIN | other | 136 |
| Jul 17, 26 | Kelly Steven | other | 136 |
| Jul 17, 26 | FAVORITO TAMARA A | other | 136 |
| Jan 30, 26 | MATSUI CONNIE | other | 292 |
| Jan 30, 26 | Blayney Douglas | other | 292 |
| Jan 30, 26 | EMANUELE ROBERT MARTIN | other | 292 |
| Jan 30, 26 | Kelly Steven | other | 292 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ARTL coverage
Recent articles, reports, and earnings notes.
No research on ARTL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ARTL report →Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13
globenewswire.com · Aug 20
Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies
globenewswire.com · Aug 17
Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results
globenewswire.com · Aug 13
Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions
globenewswire.com · Jul 16
Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026
globenewswire.com · Jul 14
Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy
globenewswire.com · Jul 13
Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy
globenewswire.com · Jul 13
Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury
globenewswire.com · Jul 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.